# GlaxoSmithKline Pharmaceuticals Ltd (GLAXO)
> Exchange: NSE | Sector: Pharma | ISIN: INE159A01016

## Price
Current Price: ₹2320.7
Day Change: -1.11%
52W High: ₹3515.95
52W Low: ₹1968
Market Cap: ₹41,331 Cr

## Valuation
P/E: 43.33
P/B: 24.2
EPS: ₹56.3
Book Value: ₹100.81
Dividend Yield: 0%

## Returns
1Y Return: -4.63%

## Profitability
ROE: 0%
ROCE: 159.39%
Debt/Equity: 0.02
Revenue Growth: 9.7%
Profit Growth: 28.6%
EBITDA Margin: 33.24%
Operating Margin: 33.71%

## About
GlaxoSmithKline Pharmaceuticals Ltd is a Drug Manufacturers - General company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - General
Sub Industry: Unknown

## Business Model
Overview: GlaxoSmithKline Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - General. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- GuruFocus.com: GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q4 2026 Earnings Call Highlights: Record PAT ...

## Access
Current tier: anonymous
More history: Register free to see 12 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:01.518Z
Price History Updated: 2026-05-18T22:58:08.890Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:08.890Z
Quant Updated: 2026-05-18T22:58:08.890Z
Sentiment Updated: 2026-05-18T22:58:08.890Z
Financials Status: current
Financials Updated: 2026-05-19T01:15:02.626Z
Financials Last Attempt: 2026-05-19T01:15:02.626Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹3726.03 Cr
Operating Profit: ₹1114.35 Cr (OPM 29.91%)
Net Profit: ₹927.58 Cr
Tax: ₹332.3 Cr

## Annual P&L History
FY25: Rev ₹3726.03Cr | PAT ₹927.58Cr | OPM 29.91%
FY24: Rev ₹3441.77Cr | PAT ₹589.96Cr | OPM 24.36%
FY23: Rev ₹3226.38Cr | PAT ₹610.69Cr | OPM 23.2%

## Balance Sheet (FY25)
Total Assets: ₹4108.07 Cr
Total Liabilities: ₹2156.75 Cr
Borrowings: ₹9.95 Cr
Cash: ₹538.85 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Bhushan  Akshikar, MD & Executive Director
- Ronojit  Biswas, CFO & Whole-Time Director
- Aparajita  Rajput, Vice President of Technology
- Ajay Avinash Nadkarni, VP of Administration & Real Estate and Company Secretary
- Amit G. Pandey, Executive Vice President of Legal

---
Source: rupiya.io/stocks/glaxo
Disclaimer: For research and education only. Not investment advice.